Clinical study
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
| Status | Invitation only |
|---|---|
| Type | Individual-case protocol |
| Countries | Canada |
| Conditions studied | Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection |
| Study years | 2026–2027 (estimated) |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage) Inclusion Criteria: * consent to participation Exclusion Criteria: * non-consent to participation
Study description
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
Study registrations
| ClinicalTrials.gov | NCT07228702 |
|---|
Recorded study locations (1)
Locations listed in the study record; this does not confirm current recruitment or treatment outside the study. A site label may be older than the overall study status.
Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic
Vancouver, British Columbia, Canada
Recorded site status: Not separately listed. Study location source ↗
Notes from the source review
- Single-patient protocol (target/actual n=1); not a broad recruiting program.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct07228702 |
|---|